Information  X 
Enter a valid email address

Tissue Regenix Group (TRX)

  Print      Mail a friend

Thursday 21 April, 2011

Tissue Regenix Group

Tissue Regenix enters commercialisation agreement

RNS Number : 3139F
Tissue Regenix Group PLC
21 April 2011
 



Tissue Regenix announces a major advance in its dCELL® Heart Valve development programme to facilitate entry into the $1.0bn heart valve market

 

 

YORK, 21 April, 2011 - Tissue Regenix, the regenerative medical device company, announces that it has entered into a commercialisation and IP agreement with one of its long term clinical collaborators, the Pontifical Catholic University of Parana (PUCPR) and Cardioprotese Ltda (representing Professor da Costa), both based in Brazil, which will facilitate the Company's entry into the $1.0bn global tissue heart valve market.

 

Under the terms of the agreement Tissue Regenix obtains exclusive worldwide commercialisation rights (excluding Brazil) to all data generated from over 8 years clinical use of decellularised human donor heart valves as heart valve replacements. The deal involves royalties but no upfront or milestone payments.

 

Highlights

  • The agreement gives Tissue Regenix exclusive worldwide rights (excluding Brazil) to the clinical data which will support commercialisation of "dCELL® Heart Valve" 
  • Tissue Regenix has obtained exclusive worldwide commercialization rights (excluding Brazil) to all future decellularised products as part of an agreed development plan which includes a decellularised version of a commercially available bioprosthetic heart valve, which has over 5 years of clinical data and has been implanted in over 1200 patients
  • Tissue Regenix will also accelerate the development of new applications for its exciting product pipeline, which includes alternate applications for its patch product and the porcine dCELL® Heart Valve, in conjunction with PUCPR utilising their world class facilities in Brazil

 

The global tissue heart valves market is expected to grow at a CAGR of 6% in the period 2009-2016, and is estimated to reach $1.430bn by 2016 (Global data report 2010). Surgical aortic valve replacement is the most common heart valve operation, accounting for 60-70% of all valve surgery in the elderly.

 

Over 140 patients have been implanted with human donor heart valves (including over 40 aortic valves) decellularised using Tissue Regenix's dCELL® technology. Initially Tissue Regenix will work with their UK development partner to transfer the technology for use in the NHS and also commercialise it in the rest of the world (excluding Brazil) via a licensing programme to other tissue banks.

 

Antony Odell, Managing Director of Tissue Regenix, commented: "The PUCPR is a world class centre in this field and Professor da Costa an internationally recognised cardiac surgeon. Alongside our existing relationship with our UK development partner, NHS Blood and Transplant, this long-term collaboration with the PUCPR and Professor da Costa is yet another example of Tissue Regenix's strategy of seeking to expand our product pipeline more rapidly and at minimum cost and development risk to the Company. The global heart valve market represents a major opportunity for Tissue Regenix, we look forward to commercializing the dCELL® Heart Valve and making this product available worldwide to surgeons and patients."

 

Of the 140 patients implanted with a dCELL® Heart Valve, 41 with aortic valves were the subject of a paper published in the journal of The Society of Thoracic Surgeons, December 2010.

 

 

Key findings

  • Improved performance over the current "gold standard": dCELL® Heart Valves were demonstrated to be less prone to calcification, a contributing factor to long term structural damage of the aortic valve, than cryopreserved donor heart valves. Some patients showed a calcium score of zero with follow-up as long as 22 months
  • Greater durability: Although cryopreserved donor heart valves have good long term results in older patients, durability is limited in younger patients, especially those less than 20 years old. dCELL® Heart Valves therefore represent a major technological advance, especially for children and young patients in whom growth potential is vital
  • More suited to younger and older patients: dCELL® Heart Valves demonstrated structural integrity and low calcification in patients aged between 1 month and 70 years old
  • Better graft survival: The results of the trial indicate that tissue engineered heart valves based on decellularised scaffolds, such as dCELL® Heart Valve, may have a significant positive impact on graft survival

 

ENDS

 

 

Enquiries:

 

Financial Dynamics  

Ben Atwell / John Dineen

+44 (0) 20 7831 3113

 

 

 

Peel Hunt LLP (Nominated Adviser)

James Steel / Vijay Barathan 

+44 (0) 20 7418 8900

 

 

 

About Tissue Regenix

 

Tissue Regenix, the RegenMed Company, was incorporated in May 2006 to commercialise the academic research of Professor Eileen Ingham and Professor John Fisher from the University of Leeds in the field of tissue decellularisation. Its dCELL® Technology comprises a patented process which removes cells and other components from human and animal tissue allowing it to be used without anti-rejection drugs to replace worn out or diseased body parts.

 

About dCELL® Technology

 

The process comprised within the dCELL® Technology involves the production of biological scaffolds created by taking a piece of human or animal tissue that is equivalent to the diseased or damaged body part which is being replaced, treating such tissue with a series of gentle chemical washes and then sterilising it. The end product is a scaffold which can be stored under normal conditions at room temperature like any synthetic medical device and, when it is implanted into the body, it repopulates with the patient's own cells using natural biological repair mechanisms.

 

Tissue Regenix's strategy is to continue to use its core dCELL® Technology as a platform to develop a range of products using the established medical device regulatory pathway to deliver solutions to unmet clinical needs. The three priority markets for the application of the technology are: Vascular (e.g. Vascular Patches); Cardiac (e.g. Heart Valves); and Orthopaedics (e.g. Meniscus).

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGREAXLEAFXFEFF

a d v e r t i s e m e n t